Vertex Ventures HC
VC Fund
Palo Alto, United States
Vertex Ventures HC is a VC fund in Palo Alto focused on Biotechnology and Health Care. Vertex Ventures HC invests in various sectors of the healthcare industry, including biopharmaceuticals, medical devices and digital health.Their portfolio includes companies at all stages of development, from early-stage companies testing transformative technologies to commercial-stage companies seeking additional growth.With a focus on areaswith significant unmet need, Vertex seeks to build great companies that improve the health and quality of human life. They take an active role in our portfolio companies and work with exceptional entrepreneurs, industry partners and fellow venture investors to create value. Their global investment professionals bring deep scientific, medical and business knowledge to every investment they make.
- Total investments:
- 45
- Last investment:
- Lead investor:
- 7%
- Fund size:
- $200M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Vertex Ventures HC invests in
Stages Vertex Ventures HC invests in
Countries Vertex Ventures HC invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Lori Hu
|
|||
Christine Brennan
|
|||
Edward Roberts
|
|||
Faheem Hasnain
|
|||
Hugh Rosen
|
Investment Focus
Industry
- Biotechnology 19 (42%)
- Health Care 15 (33%)
- Therapeutics 9 (20%)
- Medical Device 9 (20%)
- Medical 8 (18%)
Stage
- Series B 13 (29%)
- Series A 9 (20%)
- Series C 9 (20%)
- Series D 6 (13%)
- Series E 1 (2%)
Country
- United States 24 (53%)
- China 1 (2%)
- Switzerland 1 (2%)
- United Kingdom 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Lori Hu
Managing Director
|
Managing Director | Total investments: 6 | Find email | |
|
Christine Brennan
Managing Director
|
Managing Director | Total investments: 3 | Find email | |
|
Edward Roberts
Co-founder
|
Co-founder | Total investments: 0 | Find email | |
|
Faheem Hasnain
Venture Advisor
|
Venture Advisor | Total investments: 0 | Find email | |
|
Hugh Rosen
Co-founder
|
Co-founder | Total investments: 0 | Find email | |
| See all 6 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
SonoThera
|
SonoThera is a biotechnology company that creates non-viral genetic therapies using ultrasound. Its mission is to develop genetic medicines that treat the root cause of human disease. SonoThera is expanding the possibilities of disease treatment with ultrasound-guided nonviral gene therapy for diseases with suboptimal or non-existent treatments. Itaims to improve the lives and health of millions of people. | $125M / Series B / Jun 10, 2026 | |
Allay Therapeutics
|
Allay Therapeutics offers analgesic products for post-surgical pain management and recuperation. The company was founded in 2017 and is headquartered in Menlo Park, California, United States. | $57.5M / Series D / Jun 05, 2025 | |
Spyglass Pharma
|
Spyglass Pharma focuses on the development of novel treatments for chronic ophthalmic diseases based on technology. The company designs to deliver multiple drugs to address additional ophthalmic indications. | $75M / Series D / Jun 02, 2025 | |
Indapta Therapeutics
|
Indapta Therapeutics is a privately held biotechnology company developing an NK (natural killer) cell therapy platform for the treatment of blood and solid tumor cancers. | $22.5M / Venture - Series Unknown / Dec 17, 2024 | |
Moximed
|
Moximed Inc. is dedicated to improving the standard of care for patients with osteoarthritis, and is investigating therapies to treat a number of affected joints. The lead product, the KineSpring® Knee Implant System, is designed for patients with knee osteoarthritis. | $61M / Series D / Aug 13, 2024 | |
NeuSpera Medical
|
NeuSpera Medical develops implantable medical device technology to treat chronic illnesses through minimally invasive solutions. NeuSpera focuses on bioelectronic medicine and has developed ultra-miniaturized implants using their proprietary Mid-Field Powering technology. This technology allows the implants to be powered externally, enabling deeperand more reliable neuromodulation treatments for conditions like Urinary Urgency Incontinence (UUI) and chronic peripheral nerve pain | $23M / Series D / Jul 15, 2024 | |
TORL BioTherapeutics
|
TORL BioTherapeutics is a clinical-stage biopharmaceutical business focused on creating innovative, antibody-based medicines to improve the lives of cancer patients. They are developing a comprehensive pipeline of innovative preclinical ADCs and mAb in oncologic diseases with high unmet medical needs. | $158M / Series B / Apr 10, 2024 | |
Eyebiotech
|
Eyebiotech is a vision treatment company that develops products to preserve, repair, and improve eyesight. The firm guards against sight-threatening eye disorders and developed the first anti-vascular endothelial growth factor medication for patients with age-related macular degeneration, allowing those with eye ailments to regain their eyesight. | $65M / Series A / Nov 14, 2023 | |
Septerna
|
Septerna is a biotechnology company. | $150M / Series B / Jul 11, 2023 | |
|
Spyglass Pharma
|
Spyglass Pharma focuses on the development of novel treatments for chronic ophthalmic diseases based on technology. The company designs to deliver multiple drugs to address additional ophthalmic indications. | $90M / Series C / Jul 10, 2023 | |
| See all 45 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Vertex Ventures HC invest in?
Vertex Ventures HC invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series A stage. Most of the 45 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Vertex Ventures HC?
Public channels for Vertex Ventures HC include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Vertex Ventures HC?
The team at Vertex Ventures HC includes Lori Hu (Managing Director), Christine Brennan (Managing Director) and Edward Roberts (Co-founder), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
